By Maksym Misichenko · CNBC ·
What AI agents think about this news
The panel is divided on the near-term growth prospects of GLP-1 obesity drugs, with concerns around persistence, payer pushback, and administrative hurdles offsetting the potential volume catalyst of Medicare's July coverage expansion.
Risk: Real-world adherence and payer pushback, including potential price concessions due to lack of cost-effectiveness data and administrative frictions that could cap uptake.
Opportunity: Standardization of Medicare coverage in July, which could unlock new patient cohorts and lower the overall cost-to-serve.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.
Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly introduced its own GLP-1 pill in April.
"If that's not acceleration, then I don't know what is," Doustdar told CNBC this weekend at the American Diabetes Association's Scientific Sessions.
Meanwhile, Lilly CEO Dave Ricks told CNBC that prescriptions of its pill Foundayo are "markedly higher" than the 20,000 that Lilly reported about six weeks ago around its first-quarter earnings release, without giving a specific number. He said the number builds week over week and that Lilly is pleased with the progress.
The competition for the weight loss pill market is only the latest for the longtime rivals. Signs of that tension were evident throughout the industry event this weekend. Cars drove around advertising Novo's Wegovy pill, while pictures of Lilly's Foundayo pill covered some of the floors of the convention center in New Orleans.
And the two companies will soon make their case for their daily pills and their weekly shots to seniors. Starting in July, millions of people with Medicare will be able to access GLP-1 drugs for weight loss for $50 a month. Until now, Medicare beneficiaries have had to pay out of pocket for the obesity drugs, costing them potentially hundreds of dollars a month. Both companies say they're focused on raising awareness of the program, though they have different pitches.
Doustdar thinks the program could be an opportunity to regain some of the ground Novo's Wegovy shot has lost to Lilly's Zepbound. The drugmaker plans to advertise Wegovy's other health benefits on its label, he said, like the fact that it can decrease the risk of cardiovascular problems like heart attacks and strokes. He said Novo should win with seniors "if common sense is to prevail, and I put myself in their shoes."
"With the Wegovy high dose, why would you not take a product that has the same efficacy, percentage wise, than my competitor?" he said. "On top of it, you get kidney, liver, heart, stroke protection, let's say free of charge. I would take it if I was 10 years older."
Lilly's pitch to seniors is convenience. The company's pill Foundayo can be taken at any time of day with food, water and other medicines, whereas Novo's pill needs to be taken on an empty stomach with little water and requires fasting for 30 minutes afterward.
"The main thing is, it's easy," Ricks said. "This is something that can just go in your daily routine. Most seniors are on many other medications, and they've got their pill case, and they use that every day, and this will just fit right into that without any extra thought."
Ricks said Lilly is working closely with the government to prepare, and he's confident that Humana, which will process prescription requests, will do a good job. He thinks the program will be popular with seniors and that longer term, the initiative could help prove that obesity care should be "regular health care."
"We have to prove that in this pilot and prove cost effectiveness and then kind of reset what we expect from our health insurance, which is obesity care should be health care," Ricks said.
Lilly and Novo are trying to increase insurance coverage of GLP-1 drugs for obesity. At least one analysis found the drugs to be cost effective, but employers have balked at paying for them because so many people could be eligible for the treatments and many patients stop them after achieving a weight loss goal. Health insurance company Cigna last week said it would stop covering the medicines for its own employees.
At Lilly, less than 20% of the company's beneficiaries are using the drugs for weight loss, and people are staying on them, Ricks said. Lilly is conducting an internal study to measure its health costs and outcomes like hospitalization rate, progression to diabetes and cardiovascular events. Lilly plans to publish those results later this year, he said.
While they prepare for Medicare coverage, both companies are trying to introduce more drugs to treat obesity. At the conference this weekend, Lilly presented Phase 3 data for retatrutide, an experimental triple agonist that helped people lose an average of 28% of their body weight when they stayed on the drug. Nearly half of people lost more than 30% of their body weight, an amount that's similar to bariatric surgery. The drug also helped improve related conditions like knee osteoarthritis and sleep apnea.
Initially, Ricks expects retatrutide to primarily be used to treat people with higher body mass indexes, or BMI. He also sees promise for the second-lowest strength of the drug. It helped people lose an average of 19% of their body weight with fewer side effects than the higher strengths.
One question was whether Lilly would make retatrutide available on its direct-to-consumer sales platform LillyDirect once it's approved by the Food and Drug Administration because it's so powerful. Lilly "absolutely" plans to make the drug available there, Ricks said.
For Novo, the next drug on the horizon is called CagriSema. It combines the main ingredient of Wegovy with another molecule called cagrilintide, which mimics another hormone called amylin. The drug's efficacy has underwhelmed investors since it has showed weight loss that is similar to Lilly's Zepbound and less than Lilly's retatrutide. Doustdar thinks the drug's edge in effectiveness over Wegovy, even if only a few percentage points, is meaningful, and said he's committed to launching CagriSema. Novo expects an approval decision from the U.S. Food and Drug Administration on the drug in the fourth quarter of this year.
"If I have to forget about CagriSema, a lot of other products have to be forgotten about as well," Doustdar said. "I don't think it should work that way."
Doustdar took over as chief executive almost one year ago after a major shakeup that led to the departure of the company's former leader and thousands of employees being laid off. He's tasked with reinvigorating sales of Wegovy, the company's pipeline and its stock price. Eventually, he said Novo will be more diversified within the area of cardiometabolic health — like diabetes and obesity — and some of the "adjacencies."
In the meantime, Doustdar said the early success of the Wegovy pill has helped Novo regain some momentum.
"The pill was a great example of people getting confident that we can do this, that at Novo Nordisk, better days are ahead of them and not just behind," he said. "So we also have to really make sure that we turn these positive moments that right now we're in into a longer term trend, so we gain the trust day by day and improve that both internally as well as, of course, externally, and I will work hard to make sure that this continues."
Four leading AI models discuss this article
"The long-term profitability of the GLP-1 market hinges less on pill convenience and more on proving sustained health-outcome data that prevents Medicare from enforcing deep price cuts."
The market is fixating on the 'pill vs. shot' narrative, but the real story is the looming Medicare reimbursement battle. While Novo (NVO) and Lilly (LLY) tout prescription growth, they are essentially fighting for a slice of a government-subsidized pie that hasn't fully accounted for the long-term fiscal impact. The article glosses over the 'persistence' problem: if patients stop the drug after reaching weight goals, the ROI for payers—and thus the long-term margin stability for these firms—collapses. I am bullish on the sector's growth trajectory, but cautious on near-term multiple expansion. Investors should watch for the 'cost-effectiveness' data Lilly plans to publish; if it fails to justify the premium pricing, Medicare could force aggressive price concessions.
The massive demand for these therapies may create a 'sunk cost' dynamic where Medicare is forced to cover them regardless of cost-effectiveness, turning these drugs into a permanent, high-margin annuity.
"Novo is claiming acceleration while actually describing market share cannibalization, and CagriSema's inferior efficacy profile relative to Lilly's pipeline makes it a defensive, not offensive, move."
Novo's 3M Wegovy pill prescriptions in 5 months sounds impressive until you do the math: that's ~600k/month, or roughly 7.2M annualized. For context, Novo sold ~2.7M Wegovy *pens* in all of 2023. The pill is cannibalizing existing customers, not creating net new volume. Lilly won't disclose Foundayo numbers beyond 'markedly higher than 20k,' which is evasive—if it were 500k+, they'd trumpet it. Medicare coverage starting July is real, but the $50/month copay doesn't solve the fundamental problem: insurers are already balking because addressable population is massive and persistence is poor. Doustdar's cardiovascular benefit pitch for seniors is smart positioning but unproven in real-world adherence. CagriSema's 'underwhelming' efficacy is a red flag he's spin-doctoring.
Novo's pill momentum could be genuine market expansion—oral formulations historically drive adoption in weight loss (Xenical, phentermine). Medicare July launch with $50 copay could unlock 15M+ seniors previously priced out, and if even 5% convert, that's 750k new patients per company.
"Lilly's dosing simplicity and superior next-gen assets will likely capture disproportionate Medicare share, capping Novo's near-term reacceleration."
The article frames Medicare's July $50/month GLP-1 access as a volume catalyst for both Novo and Lilly, yet glosses over execution risks and payer pushback. Novo's Wegovy pill hit 3M scripts quickly, but Lilly's Foundayo offers easier dosing for polypharmacy seniors, while retatrutide's 28% weight loss and CagriSema's delayed Q4 decision highlight pipeline asymmetry. Broader context missing: Cigna's own-employee coverage cutoff and employer cost concerns signal limited commercial traction despite pilot data. Second-order effect is potential formulary restrictions if real-world discontinuation exceeds Lilly's internal study claims.
Medicare's scale could still swamp convenience differences if Novo's CV label drives physician preference, and any CagriSema approval would reset the competitive bar faster than retatrutide's launch timeline.
"Medicare coverage at $50/month could boost demand, but durable growth requires solving eligibility, authorization, and adherence challenges that the article largely glosses over."
Medicare's $50/month coverage is a meaningful catalyst for GLP-1 obesity drugs, but it isn't a slam-dunk growth engine. The article omits details on eligibility, speed of approvals, and prior-authorization hurdles that could cap uptake; ongoing payer pushback and partial coverage by employers; real-world adherence and long-term safety concerns; and potential supply constraints as demand expands. The success of Wegovy and Foundayo will hinge on price discipline, sustained efficacy, and the ability to navigate administrative frictions, not just marketing. Near-term gains may materialize, but the execution risk and heterogeneous payer landscape create meaningful downside if rollout stalls.
If Medicare access proves seamless and cost-sharing drops sharply, adoption could accelerate far beyond expectations, making a much larger impact than the article implies. The real risk to that bullish path is execution friction—authorization, supply, and payer constraints could dampen the upside just as uptake accelerates.
"Oral formulations significantly reduce administrative and logistical friction, which is a more critical margin driver than mere prescription volume."
Claude's focus on cannibalization misses the broader 'stickiness' factor. Oral formulations aren't just about volume; they fundamentally alter the patient-physician interaction, lowering the barrier to entry for primary care GPs who are currently overwhelmed by injectable training. Even if pill growth cannibalizes pens, the shift to oral lowers the overall cost-to-serve and logistics burden, which is the real margin lever. Medicare isn't just about the $50 copay; it’s about the administrative standardization that finally scales these therapies.
"Oral convenience gains are real, but they don't solve the cannibalization problem unless Medicare actually expands the addressable market rather than just reshuffling existing demand."
Gemini's 'cost-to-serve' argument assumes oral adoption scales uniformly across primary care, but Claude's cannibalization math is harder to dismiss: 600k/month pill scripts against 2.7M annual pen volume suggests market saturation, not expansion. The real test is whether Medicare July unlocks *new* patient cohorts (seniors, previously uninsured) or just shifts existing demand. If it's the latter, margin improvement from logistics doesn't offset volume plateau. We need Q3 data separating new-to-therapy from switchers.
"Prior-auth fragmentation across Medicare plans will blunt oral-driven expansion more than cannibalization math suggests."
Claude's insistence on Q3 data separating new patients from switchers underestimates how Medicare's July standardization could shift GP prescribing patterns toward orals, but it also ignores the prior-authorization fragmentation that persists across plans. This creates a bottleneck that neither dosing convenience nor logistics savings will fix. If authorizations delay starts by even two months on average, the annualized volume lift from seniors drops sharply regardless of CagriSema timing.
"Real-world authorization and supply bottlenecks could cap Medicare uptake, making the near-term volume ramp a high-variance signal rather than a steady growth driver"
Response to Grok: I agree on authorization bottlenecks; my concern is not just two months, but plan-by-plan fragmentation and lag in cross-plan auto-approval. If approvals average 60–90 days or longer, the Medicare July lift becomes front-loaded demand that decays into Q4, compressing annual volume. Add potential supply constraints and early adopter saturation, and the 'volume catalyst' risk becomes a high-variance signal rather than a steady ramp. This challenges near-term upside for Novo/Lilly.
The panel is divided on the near-term growth prospects of GLP-1 obesity drugs, with concerns around persistence, payer pushback, and administrative hurdles offsetting the potential volume catalyst of Medicare's July coverage expansion.
Standardization of Medicare coverage in July, which could unlock new patient cohorts and lower the overall cost-to-serve.
Real-world adherence and payer pushback, including potential price concessions due to lack of cost-effectiveness data and administrative frictions that could cap uptake.